Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Brivanib · BMS-540215

Small molecule · Inhibitor of VEGFR-2 (kinase insert domain receptor) (KDR) · developed by Bristol-Myers Squibb

Phase 2 Most advanced trial (none active)
1 Registered trials

What is Brivanib?

Brivanib is a pyrrolotriazine-based small molecule that inhibits vascular endothelial growth factor receptor-2 (VEGFR-2), a tyrosine kinase receptor expressed mainly on vascular endothelial cells. By blocking VEGFR-2, it is intended to inhibit VEGF-stimulated endothelial cell migration and proliferation and thereby tumor angiogenesis. It is studied in hepatocellular carcinoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
BMS-540215
Drug type
Small molecule
Targets
VEGFR-2 (kinase insert domain receptor) (KDR)
Mechanism
Inhibitor of VEGFR-2 (kinase insert domain receptor) (KDR)
Pathways
VEGF-stimulated endothelial cell migration, endothelial cell proliferation, tumor angiogenesis
Therapy area
Oncology
Developer
Bristol-Myers Squibb
In trials of
ZLAB
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
DDU33B674I

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03516071 Phase 2 Hepatocellular Carcinoma (HCC) Completed ZLAB

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hepatocellular Carcinoma (HCC)

Other drugs acting on KDR

Sources

Updated Nov 1, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.